Oncocyte Corporation  (OCX)
Other Ticker:  
Price: $3.0650 $0.02 0.528%
Day's High: $3.07 Week Perf: 2.17 %
Day's Low: $ 3.00 30 Day Perf: -6.84 %
Volume (M): 33 52 Wk High: $ 4.64
Volume (M$): $ 100 52 Wk Avg: $2.02
Open: $3.00 52 Wk Low: $0.19

 Market Capitalization (Millions $) 25,305
 Shares Outstanding (Millions) 8,256
 Employees -
 Revenues (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -77
 Cash Flow (TTM) (Millions $) -18
 Capital Exp. (TTM) (Millions $) 1

Oncocyte Corporation
Oncocyte Corporation is a healthcare company that specializes in the development of diagnostic tests for cancer. The company focuses on utilizing advanced molecular diagnostics to detect and analyze cancer cells in order to provide more accurate diagnosis and personalized treatment options for cancer patients.

Oncocyte Corporation's primary product is the DetermaRx test, which is used to determine the risk of cancer recurrence in early-stage lung cancer patients. The test analyzes the patient's tumor biology and provides information on the likelihood of their cancer returning after surgery. This can help guide treatment decisions and potentially improve patient outcomes.

In addition to the DetermaRx test, Oncocyte Corporation is also working on developing other diagnostic tests for lung, breast, and bladder cancer. These tests aim to provide clinicians with better tools for early detection, prognosis, and therapeutic guidance.

The company collaborates with academic institutions, research organizations, and healthcare practitioners to advance their diagnostic technologies. They are committed to improving patient care by providing accurate and reliable diagnostic tools that enable personalized treatment approaches in the fight against cancer.

   Company Address: 15 Cushing Irvine 92618 CA
   Company Phone Number: 409-7600   Stock Exchange / Ticker: NASDAQ OCX
   OCX is expected to report next financial results on April 11, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Oncocyte Corporation

Oncocyte Corporation's Revenue Surges in Q3 2023, but Profitability Remains Elusive

Oncocyte Corporation, a leading player in the In Vitro & In Vivo Diagnostic Substances industry, recently released its financial results for the third quarter of 2023. Despite reporting a significant increase in revenue compared to the same period last year, the company witnessed a widening of its losses. This article will outline the key facts from Oncocyte Corporation's financial results and provide context to better understand the company's performance in the industry.
Revenue Growth and Comparisons:
Oncocyte Corporation announced an impressive year-on-year revenue advancement of 946.341% in the third quarter of 2023, reaching $0.43 million. This growth significantly outperformed its industry peers, who reported an aggregated 11.10% top-line advance during the same period. However, it is important to note that the company's revenue deteriorated by -7.343% from the previous reporting season, where it recorded $0.46 million in revenue.

Oncocyte Corporation

Oncocyte Corporation Stumbles as Revenues Plummet 57.562% in Q2 2023, Raising Investor Alarm

In the wake of the most recent fiscal period, Oncocyte Corporation has unveiled concerning financial results, reporting a drastic decline in revenue and a significant increase in net loss per share. While the rest of the In Vitro & In Vivo Diagnostic Substances sector saw positive growth, Oncocyte Corporation struggled to maintain its foothold. This article seeks to shed light on the implications of the company's performance and its contrasting market sentiment.
Revenues and Net Loss Per Share:
Oncocyte Corporation's revenues plummeted by an alarming 57.562% to a mere $0.46 million in the most recent fiscal period. This decrease is significant, especially when compared to the corresponding financial report from the previous year. The net loss per share also stands out, swelling to $-1.07, further amplifying concerns among investors.


Oncocyte's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com